You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information. Do Not Sell or Share My Persona...
Events and presentations April 15, 2025 Johnson & Johnson First Quarter 2025 Earnings Call and Webcast See details(opens in new window) March 4, 2025 TD Cowen 45th Annual Health Care Conference Webcast(opens in new window) See details(opens in new window) ...
Financials & Filings Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance Stock Information $131.690 (0.00%) Previous Close $131.69 Open -- Volume 0 Exchange NASDAQ 52 Week High $131.79
Visitor experiences include narrative “deep dives” into key themes in Johnson & Johnson’s history; a timeline that juxtaposes the Company’s history with current world events; an interactive map highlighting how we’re improving the health and lives of people worldwide and comprehensive digital ...
• 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* • 2024 Second-Quarter Earnings per share
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...
Adds V-Wave’s Novel and Minimally Invasive Ventura® Interatrial Shunt to the Johnson & Johnson MedTech Portfolio Strengthens Johnson & Johnson MedTech’s Position in Cardiovascular Disease
TheMotley Fool Stock Advisoranalyst team just identified what they believe are the10 best stocksfor investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. ...
Johnson& Johnson 1 today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, John
Johnson & Johnson Vision and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments. About Johnson & Johnson Vision* At Johnson & Jo...